BR112021019113A2 - Conjugados de hialuronano e usos dos mesmos - Google Patents
Conjugados de hialuronano e usos dos mesmosInfo
- Publication number
- BR112021019113A2 BR112021019113A2 BR112021019113A BR112021019113A BR112021019113A2 BR 112021019113 A2 BR112021019113 A2 BR 112021019113A2 BR 112021019113 A BR112021019113 A BR 112021019113A BR 112021019113 A BR112021019113 A BR 112021019113A BR 112021019113 A2 BR112021019113 A2 BR 112021019113A2
- Authority
- BR
- Brazil
- Prior art keywords
- hyaluronan
- conjugates
- sex hormone
- hyaluronan conjugates
- document
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title abstract 7
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title abstract 4
- 229940099552 hyaluronan Drugs 0.000 title abstract 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 3
- 229960003160 hyaluronic acid Drugs 0.000 abstract 3
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000600 disaccharide group Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
conjugados de hialuronano e usos dos mesmos. o presente documento revela um conjugado de hialuronano, que inclui um ácido hialurônico (ha), um hormônio sexual e um ligante para acoplar uma das unidades de dissacarídeo de ha e o hormônio sexual. também são revelados neste documento os usos do conjugado de hialuronano no tratamento ou prevenção de doenças neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856714P | 2019-06-03 | 2019-06-03 | |
| PCT/US2020/035780 WO2020247407A1 (en) | 2019-06-03 | 2020-06-02 | Hyaluronan conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019113A2 true BR112021019113A2 (pt) | 2021-12-14 |
Family
ID=73550112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019113A BR112021019113A2 (pt) | 2019-06-03 | 2020-06-02 | Conjugados de hialuronano e usos dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11524079B2 (pt) |
| EP (2) | EP3976019A4 (pt) |
| JP (1) | JP7275320B2 (pt) |
| CN (1) | CN113660933B (pt) |
| AU (1) | AU2020288834B2 (pt) |
| BR (1) | BR112021019113A2 (pt) |
| CA (1) | CA3133671C (pt) |
| CO (1) | CO2021012240A2 (pt) |
| EA (1) | EA202192225A1 (pt) |
| IL (1) | IL287917A (pt) |
| MX (1) | MX2021013140A (pt) |
| SA (1) | SA521430791B1 (pt) |
| SG (1) | SG11202109152UA (pt) |
| TW (2) | TWI737330B (pt) |
| WO (2) | WO2020247407A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024080183A1 (ja) * | 2022-10-14 | 2024-04-18 | 国立大学法人東海国立大学機構 | 糖鎖複合体、薬物担体、及びドラッグデリバリーシステム |
| CN115970046B (zh) * | 2022-12-02 | 2024-04-26 | 南京工业大学 | 一种多功能水凝胶在制备治疗糖尿病伤口药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002257430A1 (en) * | 2001-05-01 | 2002-11-11 | Mcgill University | Androgen-mediated neuroprotection and uses thereof |
| AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
| US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
| EP2468282A3 (en) * | 2005-07-12 | 2012-09-12 | DMI Biosciences, Inc. | Methods and products for treatment of diseases |
| CA2616607C (en) | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| KR100806088B1 (ko) | 2007-08-09 | 2008-02-21 | 고려대학교 산학협력단 | 히알루론산과 폴리에틸렌이민으로 이루어진 양이온성고분자 접합체를 이용한 핵산 전달용 조성물 |
| IE20070900A1 (en) * | 2007-12-12 | 2009-06-24 | Eurand Pharmaceuticals Ltd | New anticancer conjugates |
| WO2011148116A2 (fr) | 2010-05-27 | 2011-12-01 | Laboratoire Idenov | Acide hyaluronique modifie, procede de fabrication et utilisations |
| US8895069B2 (en) | 2011-05-16 | 2014-11-25 | Postech Academy-Industry Foundation | Drug delivery system using hyaluronic acid-peptide conjugate micelle |
| US20130116411A1 (en) | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Methods of making hyaluronic acid/collagen compositions |
| CN104603156B (zh) * | 2012-09-05 | 2016-10-26 | 中外制药株式会社 | 引入有氨基酸和甾基的透明质酸衍生物 |
| AU2014225682A1 (en) * | 2013-03-08 | 2015-09-24 | Allergan, Inc. | Antibiotic conjugates linked with steroid drugs |
| EP2981556A4 (en) * | 2013-04-02 | 2016-11-30 | Univ California | HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE |
| US9572832B2 (en) | 2013-08-29 | 2017-02-21 | Holy Stone Healthcare Co., Ltd. | Compound of glycosaminoglycan and its fabrication method as well as application |
| AU2015287696B2 (en) * | 2014-07-10 | 2018-06-14 | Academia Sinica | Multi-drug delivery system and uses thereof |
| US20160279108A1 (en) * | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
| KR101818705B1 (ko) | 2015-07-20 | 2018-01-16 | 포항공과대학교 산학협력단 | 약물이 충전된 히알루론산 가교물 하이드로겔 및 이의 이용 |
| US20190015518A1 (en) | 2016-01-04 | 2019-01-17 | University Of Kansas | Drug delivery compositions and methods |
| CZ2016826A3 (cs) | 2016-12-22 | 2018-07-04 | Contipro A.S. | Léčivý prostředek s nosičem na bázi hyaluronanu a/nebo jeho derivátů, způsob výroby a použití |
| TWI626043B (zh) * | 2017-06-13 | 2018-06-11 | 心悅生醫股份有限公司 | 苯甲酸鋰用於治療中樞神經系統疾病的用途 |
| TW201912152A (zh) * | 2017-08-30 | 2019-04-01 | 保羅 L 曼弗雷蒂 | 用於治療或預防神經系統病症及其症狀及表現、以及用於對抗疾病及細胞老化及其症狀及表現之細胞保護之化合物 |
-
2020
- 2020-06-02 WO PCT/US2020/035780 patent/WO2020247407A1/en active Application Filing
- 2020-06-02 CN CN202080016386.9A patent/CN113660933B/zh active Active
- 2020-06-02 SG SG11202109152UA patent/SG11202109152UA/en unknown
- 2020-06-02 EP EP20818542.1A patent/EP3976019A4/en active Pending
- 2020-06-02 BR BR112021019113A patent/BR112021019113A2/pt unknown
- 2020-06-02 MX MX2021013140A patent/MX2021013140A/es unknown
- 2020-06-02 US US16/891,020 patent/US11524079B2/en active Active
- 2020-06-02 JP JP2021568410A patent/JP7275320B2/ja active Active
- 2020-06-02 CA CA3133671A patent/CA3133671C/en active Active
- 2020-06-02 EA EA202192225A patent/EA202192225A1/ru unknown
- 2020-06-02 AU AU2020288834A patent/AU2020288834B2/en active Active
- 2020-06-03 TW TW109118583A patent/TWI737330B/zh active
- 2020-12-10 WO PCT/US2020/064293 patent/WO2021247076A1/en unknown
- 2020-12-10 EP EP20938836.2A patent/EP4157256A4/en active Pending
- 2020-12-11 TW TW109143747A patent/TWI817065B/zh active
-
2021
- 2021-09-17 CO CONC2021/0012240A patent/CO2021012240A2/es unknown
- 2021-11-08 SA SA521430791A patent/SA521430791B1/ar unknown
- 2021-11-08 IL IL287917A patent/IL287917A/en unknown
-
2022
- 2022-11-02 US US17/979,450 patent/US20230080473A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL287917A (en) | 2022-01-01 |
| TWI817065B (zh) | 2023-10-01 |
| EA202192225A1 (ru) | 2022-03-15 |
| EP3976019A1 (en) | 2022-04-06 |
| TW202110456A (zh) | 2021-03-16 |
| NZ779338A (en) | 2024-04-26 |
| WO2020247407A1 (en) | 2020-12-10 |
| US20200376132A1 (en) | 2020-12-03 |
| AU2020288834A1 (en) | 2021-09-16 |
| SG11202109152UA (en) | 2021-12-30 |
| AU2020288834B2 (en) | 2022-12-22 |
| CA3133671C (en) | 2023-12-19 |
| JP2022539652A (ja) | 2022-09-13 |
| TWI737330B (zh) | 2021-08-21 |
| WO2021247076A1 (en) | 2021-12-09 |
| MX2021013140A (es) | 2021-12-10 |
| US20230080473A1 (en) | 2023-03-16 |
| EP4157256A4 (en) | 2024-07-31 |
| EP4157256A1 (en) | 2023-04-05 |
| US11524079B2 (en) | 2022-12-13 |
| CN113660933A (zh) | 2021-11-16 |
| EP3976019A4 (en) | 2023-03-01 |
| CO2021012240A2 (es) | 2021-09-30 |
| TW202146051A (zh) | 2021-12-16 |
| KR20210151062A (ko) | 2021-12-13 |
| SA521430791B1 (ar) | 2024-07-15 |
| JP7275320B2 (ja) | 2023-05-17 |
| CN113660933B (zh) | 2023-12-01 |
| CA3133671A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| BR112012030337A2 (pt) | vacinas compreendendo colesterol e cpg como moléculas veículo-adjuvante exclusivas e uso das mesmas | |
| UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
| BR112019012883A2 (pt) | conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis | |
| BR112021019113A2 (pt) | Conjugados de hialuronano e usos dos mesmos | |
| BR112018011228A2 (pt) | tratamentos de combinação e seus usos e métodos | |
| BR112018006817A2 (pt) | método de tratamento do câncer | |
| MX2024008222A (es) | Hidrogeles de acido hialuronico degradables. | |
| BR112022019532A2 (pt) | Conjugados de neodegrader | |
| BR112022013746A2 (pt) | Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112022008365A2 (pt) | Inibidores de cd73 | |
| BR112022005465A2 (pt) | Conjugados de proteína-macromolécula e métodos de uso dos mesmos | |
| BR112022010411A2 (pt) | Composições bacterianas projetadas e usos das mesmas | |
| WO2018154118A3 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| MX2021003186A (es) | Nuevos conjugados de hidrogel. | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas | |
| BR112018003455A2 (pt) | composição ou composição farmacêutica e uso da composição | |
| BR112021024285A2 (pt) | Vetores aav com promotor da proteína zero da mielina e usos dos mesmos para tratar doenças associadas a células de schwann como doença de charcot marie tooth | |
| BR112022000710A2 (pt) | Vacina viral terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |